John T. Mondick, Ph.D.

Principal Scientist, Group Leader

John has 5 years of experience in the pharmaceutical industry and academia applying modeling and simulation to problems in clinical pharmacology. John’s interests include the application of modeling and simulation in pediatric pharmacology and the development of mechanistic models to optimize decision making in drug development.

Recent publications by this scientist

Animal-to-human dose translation of obiltoxaximab for treatment of inhalational anthrax under the US FDA animal rule.

December 1, 2016

Nagy CF, Mondick J, Serbina N, Casey LS, Carpenter SE, French J, Guttendorf R.  Clinical And Translational Science, 2016 Dec; 10: 12–19.

Download PDF

Efficacy projection of obiltoxaximab for treatment of inhalational anthrax across a range of disease severity

October 1, 2016

Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, O’Connor E, Gonzales N, Mondick J, French J, Stark GV, Fisher AC, Casey LS, Serbina NV. Antimicrob Agents Chemother 60:5787–5795. doi:10.1128/AAC.00972-16

Download PDF

Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes

March 26, 2016

Mondick J, Riggs M, Sasaki T, Sarashina A, Broedl UC, Retlich S. Diabetes Obes Metab. 2016 Mar;18(3):241-8.

Download PDF